IP Library Granted Patent US 9,227,917
Granted Patent B2
US 9,227,917 · App. 14/089,603 · Granted Jan 5, 2016

Amine-containing lipidoids and uses thereof

Inventors: Daniel Griffith Anderson (Framingham, MA); Kathryn Ann Whitehead (Pittsburgh, PA); Joseph R. Dorkin (Somerville, MA); Arturo Jose Vegas (Cambridge, MA); Yunlong Zhang (Cambridge, MA); Robert S. Langer (Newton, MA)
Assignee: Massachusetts Institute of Technology
C07C229/26A61K9/1272A61K9/5123A61K31/225A61K31/24A61K31/357A61K31/40A61K31/445A61K31/495A61K31/4965A61K31/4985A61K31/573A61K31/704A61K31/713A61K45/06A61K47/48038A61K47/48046A61K47/48869C07C229/12C07C229/14C07C229/24C07C229/28C07C229/34C07D207/09C07D211/14C07D211/26C07D211/34C07D241/04C07D295/13C07D295/15C07D319/16C07D319/18C07D487/04C12N15/111C12N15/88A61K47/18C07C2101/14C12N2310/14C12N2320/32
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,227,917
App. No.
14/089,603
Granted
Jan 5, 2016
Kind
B2
Abstract

Provided herein are lipidoids that may be prepared from the conjugate addition of alkylamines to acrylates. In some embodiments, provided lipidoids are biodegradable and may be used in a variety of drug delivery systems. Given the amino moiety of the lipidoids, they are well-suited for the delivery of polynucleotides, in addition to other agents. Nanoparticles containing the inventive lipidoids and polynucleotides have been prepared and have been shown to be effective in delivering siRNA.

Claims (42)

1. A compound of Formula (I):

or a salt thereof,

wherein

each L is, independently, branched or unbranched C 1-6 alkylene, wherein L is optionally substituted with one or more fluorine radicals;

each R A is, independently, branched or unbranched C 1-6 alkyl, C 3-7 cycloalkyl, or branched or unbranched C 4-12 cycloalkylalkyl, wherein R A is optionally substituted with one or more fluorine radicals;

each R is, independently, hydrogen, or —CH 2 CH 2 C(═O)OR B , provided that at least three R groups are —CH 2 CH 2 C(═O)OR B ;

each R B is, independently, C 10-14 alkyl, wherein R B is optionally substituted with one or more fluorine radicals; and

q is 1, 2, or 3;

provided that the compound is not

2. The compound of claim 1 , wherein the compound is of the Formula (I-a):

or a salt thereof, wherein

each n is, independently, 0, 1, or 2; and

m is 0, 1, or 2.

3. The compound of claim 1 , wherein L is unbranched C 1-6 alkylene.

4. The compound of claim 1 , wherein the compound is of the formula

or a salt thereof.

5. The compound of claim 1 , wherein the compound is of the formula:

or a salt thereof.

6. The compound of claim 1 , wherein all R groups are —CH 2 CH 2 C(═O)OR B .

7. The compound of claim 1 , wherein all R B groups are the same.

8. The compound of claim 1 , wherein R B is C 10 alkyl, C 11 alkyl, C 12 alkyl, C 13 alkyl, or C 14 alkyl.

9. A compound selected from the group consisting of:

and salts thereof.

10. A nanoparticle comprising a compound of claim 1 and one or more agents to be delivered.

11. The nanoparticle of claim 10 , wherein the one or more agents is a polynucleotide, drug, protein, peptide, a small molecule, or gas.

12. A composition comprising one or more compounds of claim 1 , and an excipient.

13. The composition of claim 12 , wherein the composition further comprises an agent selected from the group consisting of an organic molecule, inorganic molecule, nucleic acid, protein, peptide, polynucleotide, targeting agent, an isotopically labeled chemical compound, vaccine, and an immunological agent.

14. A method of administering an agent, the method comprising:

administering to a subject in need thereof a therapeutically effective amount of a composition comprising a compound of claim 1 and an agent to be delivered.

15. The compound of claim 1 , wherein L is ethylene.

16. The compound of claim 1 , wherein L is propylene.

17. The compound of claim 1 , wherein q is 1.

18. The compound of claim 1 , wherein q is 2.

19. The compound of claim 1 , wherein q is 3.

20. The compound of claim 1 , wherein R A is branched or unbranched C 1-6 alkyl.

21. The compound of claim 1 , wherein R A is methyl, ethyl, or propyl.

22. The compound of claim 1 , wherein R A is C 3-7 cycloalkyl.

23. The nanoparticle of claim 11 , wherein the one or more agents is a polynucleotide, and the polynucleotide is RNA.

24. The composition of claim 13 , wherein the agent is a polynucleotide, and the polynucleotide is DNA.

25. The composition of claim 13 , wherein the agent is a polynucleotide, and the polynucleotide is RNA.

26. The composition of claim 25 , wherein the RNA is mRNA, dsRNA, siRNA, shRNA, miRNA, or antisense RNA.

27. The composition of claim 13 , wherein the agent is a polynucleotide, and the polynucleotide encodes a protein or peptide.

Assignments (2)
CONFIRMATORY LICENSE Recorded Apr 16, 2015
From: MASSACHUSETTS INSTITUTE OF TECHNOLOGY
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 035440/0050 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 30, 2014
From: ANDERSON, DANIEL GRIFFITH; WHITEHEAD, KATHRYN ANN; DORKIN, JOSEPH R.; VEGAS, ARTURO JOSE; ZHANG, YUNLONG; LANGER, ROBERT S.
To: MASSACHUSETTS INSTITUTE OF TECHNOLOGY
Reel/Frame 033420/0314 →
Continuity (3)
Continuation 13966136 · Aug 13, 2013
Provisional Application 61682468 · Aug 13, 2012
Related Publication 20140161830A1 · Jun 12, 2014